Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05501769 |
| Title | ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (TACTIVE-E) |
| Acronym | TACTIVE-E |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Arvinas Estrogen Receptor, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | ESP |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Clinical Trial Site | San Diego | California | 92037 | United States | Details | |
| Clinical Trial Site | Santa Monica | California | 90404 | United States | Details | |
| Clinical Trial Site | Washington | District of Columbia | 20007 | United States | Details | |
| Clinical Trial Site | Lake Mary | Florida | 32746 | United States | Details | |
| Clinical Trial Site | Ann Arbor | Michigan | 48109 | United States | Details | |
| Clinical Trial Site | Nashville | Tennessee | 37203 | United States | Details | |
| Clinical Trial Site | Barcelona | 08028 | Spain | Details | ||
| Clinical Trial Site | Madrid | 28034 | Spain | Details | ||
| Clinical Trial Site | Valencia | 46018 | Spain | Details |